PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics today announced the appointment of William R. Hinshaw as the Chief Executive Officer and Director of the Board.

费城--（商业新闻短讯）--FORE Biotherapeutics今天宣布任命William R.Hinshaw为首席执行官兼董事会董事。

Mr. Hinshaw is a 30+-year veteran of the biotechnology and pharmaceutical industries. Prior to joining Fore, he was the President, CEO and Board member of Axcella Therapeutics, a clinical-stage and publicly traded biopharmaceutical company developing novel therapies for complex diseases. Prior to Axcella, Mr.

辛肖先生在生物技术和制药行业有30多年的经验。在加入Fore之前，他是Axcella Therapeutics的总裁、首席执行官和董事会成员，Axcella Therapeutics是一家临床阶段和上市生物制药公司，开发针对复杂疾病的新型疗法。在Axcella之前。

Hinshaw led all aspects of Novartis’ >$6B revenue U.S. Oncology business, including products such as Tasigna®, Gleevec®, and Kymriah®, as well as the integration of the GSK oncology portfolio, including Tafinlar® and Mekinist®. He also played a key role on the Global Oncology Executive Committee, including leading crucial strategic programs to maximize the portfolio and develop the pipeline..

辛肖领导了诺华60亿美元收入的美国肿瘤学业务的各个方面，包括Tasigna®、Gleevec®和Kymriah®等产品，以及GSK肿瘤学组合的整合，包括Tafinlar®和Mekinist®。他还在全球肿瘤学执行委员会中发挥了关键作用，包括领导关键的战略计划，以最大限度地扩大投资组合并开发管道。。

Prior to this role, Mr. Hinshaw held a number of leadership positions of increasing responsibility and expanding global scope at Novartis, including Head of the NCE (Northern and Central Europe) Region for Novartis Oncology, GEM (Group Emerging Markets), Head of the Hematology Business Franchise, and Global Head of Infectious Disease and Transplantation (IDTI).

在此之前，Hinshaw先生曾在诺华担任多个领导职位，负责增加职责并扩大全球范围，包括诺华肿瘤学NCE（北欧和中欧）地区负责人、GEM（集团新兴市场）、血液学业务特许经营负责人以及传染病和移植（IDTI）全球负责人。

Before joining Novartis, Bill worked at the former Schering Plough Corporation where he held a series of commercial roles, including the Head of US Oncology. Mr. Hinshaw holds a B.S. in Molecular Biology from the University of Wisconsin..

在加入诺华之前，比尔曾在前先灵葆雅公司工作，在那里他担任过一系列商业角色，包括美国肿瘤学负责人。Hinshaw先生拥有威斯康星大学分子生物学学士学位。。

Dieter Weinand, the Chairman of the Board of Directors commented: “After an extensive search, we are delighted and very excited to welcome Bill as our next CEO. Bill brings highly relevant experience to grow and scale Fore given his track record in both large and emerging life sciences companies. He is the right leader for this stage of our company’s journey and the Board and I are delighted to partner with Bill to navigate Fore’s path to continued success.”.

Dieter Weinand，董事会主席评论道：“经过广泛的搜索，我们很高兴也非常兴奋地欢迎比尔担任我们的下一任首席执行官。比尔在大型和新兴生命科学公司都有着良好的业绩记录，他为Fore带来了高度相关的成长和规模。他是我们公司旅程和董事会现阶段的正确领导者，我很高兴与比尔合作，引领Fore继续取得成功s、 “。

“I am privileged and excited to lead Fore and work alongside the talented and committed team and build upon what has been accomplished to date. Fore is poised to develop targeted treatments that can have a transformational impact on the lives of patients suffering from cancer,” said Mr. Hinshaw.

辛肖先生说：“我很荣幸也很兴奋能够领导Fore，与才华横溢、兢兢业业的团队一起工作，并在迄今为止所取得的成就的基础上再接再厉。Fore准备开发有针对性的治疗方法，可以对癌症患者的生活产生变革性的影响。”。

“On behalf of the Board of Directors, I would like to sincerely thank Dr. Shawn M. Leland, PharmD, RPh for his leadership, dedication and many contributions during this transitionary period toward the advancement of plixorafenib to its next seminal phase of clinical development as Advisor and Interim CEO to the Company,” said Dieter Weinand, Chairman of the Board of FORE Biotherapeutics.

FORE Biotherapeutics董事会主席Dieter Weinand表示：“我谨代表董事会，衷心感谢RPh PharmD Shawn M.Leland博士在这一过渡时期的领导，奉献精神和许多贡献，他作为公司顾问和临时CEO，为普利索拉非尼进入下一个开创性的临床开发阶段做出了贡献。”。

“We welcome Bill as CEO and Board member as we enter this next phase of growth for the company.”.

“随着公司进入下一个增长阶段，我们欢迎比尔担任首席执行官和董事会成员。”。

About Plixorafenib

关于Plixorafenib

Plixorafenib is an investigational, novel, small-molecule, next-generation, orally available selective inhibitor of mutated BRAF. It was designed to target a wide range of BRAF mutations while sparing wild-type forms of RAF. Preclinical studies and clinical trials have shown that its unique mechanism of action effectively inhibits not only the constitutively active BRAFV600 monomers targeted by first-generation RAF inhibitors but also disrupts constitutively active dimeric BRAF class 2 mutants, fusions, splice variants and others.

Plixorafenib是一种研究性的，新型的，小分子的，下一代的，口服的突变BRAF选择性抑制剂。它被设计用于靶向广泛的BRAF突变，同时保留野生型RAF。临床前研究和临床试验表明，其独特的作用机制不仅有效抑制了第一代RAF抑制剂靶向的组成型活性BRAFV600单体，而且破坏了组成型活性二聚体BRAF 2类突变体，融合体，剪接变体等。

Unlike first-generation RAF inhibitors, plixorafenib does not induce paradoxical activation of the RAF/MEK/ERK pathway. As a “paradox breaker”, plixorafenib could therefore treat acquired resistance to current RAF inhibitors and, more generally, yield improved safety and more durable efficacy than first-generation RAF inhibitors..

与第一代RAF抑制剂不同，plixorafenib不会诱导RAF/MEK/ERK途径的矛盾激活。因此，作为“悖论破坏者”，plixorafenib可以治疗对当前RAF抑制剂的获得性耐药，并且更普遍地说，与第一代RAF抑制剂相比，可以提高安全性和更持久的疗效。。

Plixorafenib is currently being evaluated in Phase 1/2a clinical trial in patients with advanced solid tumors (including brain and spinal cord tumors) with activating BRAF alterations. Interim clinical data presented at ESMO 2022, ASCO 2023 and SNO 2023 provided evidence of durable anti-tumor activity in patients with BRAF-mutated cancers..

Plixorafenib目前正在1/2a期临床试验中对具有激活BRAF改变的晚期实体瘤（包括脑和脊髓肿瘤）患者进行评估。在ESMO 2022，ASCO 2023和SNO 2023上提供的中期临床数据提供了BRAF突变癌症患者持久抗肿瘤活性的证据。。

About FORE Biotherapeutics

关于FORE生物治疗学

Fore Bio is a precision oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company’s lead asset plixorafenib (FORE8394; formerly PLX8394) is an inhibitor of BRAF dimerization allowing for the targeting of V600 and non-V600 driven tumors.

Fore Bio是一家精密肿瘤学公司，致力于开发创新疗法，为最难治疗的癌症患者提供更好的治疗效果。该公司的主要资产plixorafenib（FORE8394；以前的PLX8394）是BRAF二聚化的抑制剂，可以靶向V600和非V600驱动的肿瘤。

In Phase 1/2a, plixorafenib demonstrated deep and durable responses in V600-mutated MAPK inhibitor-naïve patients, including a 42% overall response in patients with solid tumors with a median duration of response of 17.8 months and a 67% overall response rate in patients with primary central nervous system tumors with a median duration of response of 13.9 months.

在1/2a期，plixorafenib在V600突变的MAPK抑制剂初治患者中表现出深度和持久的反应，其中实体瘤患者的总反应率为42%，中位反应持续时间为17.8个月，原发性中枢神经系统肿瘤患者的总反应率为67%，中位反应持续时间为13.9个月。

Plixorafenib is currently being investigated in the ongoing, potentially registrational Phase 2 FORTE study. For more information, please visit www.fore.bio or follow us on X (formerly Twitter) and LinkedIn..

Plixorafenib目前正在进行正在进行的潜在注册2期FORTE研究中进行调查。有关更多信息，请访问www.fore.bio或在X（以前的Twitter）和LinkedIn上关注我们。。